Edition:
United Kingdom

Aeglea Bio Therapeutics Inc (AGLE.OQ)

AGLE.OQ on NASDAQ Stock Exchange Global Market

6.99USD
22 Jul 2019
Change (% chg)

$-0.01 (-0.14%)
Prev Close
$7.00
Open
$7.01
Day's High
$7.10
Day's Low
$6.96
Volume
11,842
Avg. Vol
54,692
52-wk High
$11.16
52-wk Low
$5.99

Latest Key Developments (Source: Significant Developments)

Aeglea Biotherapeutics Reports Fourth Quarter And Full Year 2018 Financial Results
Thursday, 7 Mar 2019 

March 7 (Reuters) - Aeglea Bio Therapeutics Inc ::AEGLEA BIOTHERAPEUTICS REPORTS FOURTH QUARTER AND FULL YEAR 2018 FINANCIAL RESULTS AND CORPORATE HIGHLIGHTS.AEGLEA BIO THERAPEUTICS INC - ON TRACK TO DOSE FIRST PATIENT IN PIVOTAL PHASE 3 TRIAL OF PEGZILARGINASE FOR ARG1-D IN Q2 OF 2019.AEGLEA BIO THERAPEUTICS INC - PROGRESS WITH PEGZILARGINASE CANCER INDICATION-PHASE 2 COMBINATION STUDY INITIATED.AEGLEA BIO THERAPEUTICS INC - AS OF DECEMBER 31, 2018, AEGLEA HAD AVAILABLE CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES OF $74.5 MILLION.  Full Article

Aeglea Bio Therapeutics Says Co Intends To Offer And Sell Up To $50 Mln Of Shares Of Its Common Stock
Tuesday, 5 Feb 2019 

Feb 5 (Reuters) - Aeglea Bio Therapeutics Inc ::AEGLEA BIOTHERAPEUTICS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK.AEGLEA BIO THERAPEUTICS INC - INTENDS TO OFFER AND SELL UP TO $50.0 MILLION OF SHARES OF ITS COMMON STOCK.AEGLEA BIO THERAPEUTICS - INTENDS TO USE PROCEEDS TO ADVANCE CLINICAL DEVELOPMENT OF PEGZILARGINASE THROUGH PHASE 3 PIVOTAL, EXTENSION TRIALS IN ARGINASE 1 DEFICIENCY.  Full Article

Aeglea Bio Therapeutics Entered Master Services Agreement With Fujifilm Units
Thursday, 29 Nov 2018 

Nov 29 (Reuters) - Aeglea Bio Therapeutics Inc ::AEGLEA BIO THERAPEUTICS - ON NOVEMBER 26, ENTERED MASTER SERVICES AGREEMENT WITH FUJIFILM UNITS - SEC FILING.AEGLEA BIO THERAPEUTICS - FUJIFILM WILL PROVIDE RESEARCH, DEVELOPMENT, TESTING & MANUFACTURING SERVICES OF CERTAIN OF CO'S PRODUCTS.  Full Article

Aeglea Biotherapeutics Qtrly Net Loss $0.54
Thursday, 8 Nov 2018 

Nov 8 (Reuters) - Aeglea Bio Therapeutics Inc ::AEGLEA BIOTHERAPEUTICS REPORTS THIRD QUARTER 2018 FINANCIAL RESULTS AND RECENT CORPORATE HIGHLIGHTS.AEGLEA BIO THERAPEUTICS INC - AS OF SEPTEMBER 30, 2018, CO HAD AVAILABLE CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES OF $64.7 MILLION.AEGLEA BIO THERAPEUTICS INC QTRLY NET LOSS $0.54.  Full Article

Aeglea Biotherapeutics Announces Proposed Public Offering
Tuesday, 17 Apr 2018 

April 17 (Reuters) - Aeglea Bio Therapeutics Inc ::AEGLEA BIOTHERAPEUTICS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK.SAYS OFFERING 4.50 MILLION COMMON SHARES.  Full Article

Aeglea Biotherapeutics announces clinical collaboration with Merck
Monday, 16 Oct 2017 

Oct 16 (Reuters) - Aeglea Bio Therapeutics Inc :Aeglea Biotherapeutics announces clinical collaboration with Merck to evaluate the combination of Aeglea’S AEB1102 (pegzilarginase) with Merck's Keytruda® (pembrolizumab) for the treatment of small cell lung cancer.Aeglea Bio Therapeutics Inc - ‍collaboration agreement is between Aeglea Biotherapeutics and Merck, through a subsidiary​.Aeglea Bio Therapeutics Inc - ‍additional details of collaboration were not disclosed​.Aeglea Bio Therapeutics Inc - ‍enrollment to multicenter phase 1/2 study​ is expected to begin in Q1 of 2018.  Full Article

Aeglea Bio Therapeutics doses 2 patients in repeat dose as part of clinical trial
Wednesday, 6 Sep 2017 

Sept 6 (Reuters) - Aeglea Bio Therapeutics Inc :Aeglea Bio Therapeutics doses two patients in repeat dose part of phase 1/2 clinical trial for the treatment of arginase 1 deficiency.Aeglea Bio Therapeutics -‍dosed 2 adults in repeat dose part of phase 1/2 clinical trial of AEB1102 for treatment of patients with Arginase 1 Deficiency​.  Full Article

Aeglea BioTherapeutics reports Q2 loss per share $0.47‍​
Wednesday, 9 Aug 2017 

Aug 10 (Reuters) - Aeglea BioTherapeutics Inc -:Aeglea BioTherapeutics provides corporate update and reports second quarter 2017 financial results.Q2 revenue $1.5 million versus I/B/E/S view $1.3 million.Aeglea BioTherapeutics - qtrly loss per share $0.47‍​.  Full Article

IFR Americas ECM Weekly Wrap

US WEEKLY TOTAL $3,418.3m – IPO $927.0m – ABB/BLOCK $630.7m – FOLLOW-ON $1,375.0m – CB $485.0m Monday Dream Industrial REIT (Canada, industrial REIT) – C$125m Block. 12m units (100% sec) at C$10.45 versus C$10.77 last sale. TD.